Trials / Completed
CompletedNCT02724254
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 218 (actual)
- Sponsor
- Vaxart · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AP611074 5% gel | |
| DRUG | AP611074 matching placebo |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-05-01
- Completion
- 2018-07-01
- First posted
- 2016-03-31
- Last updated
- 2018-07-20
Locations
12 sites across 4 countries: Argentina, Chile, Ecuador, Serbia
Source: ClinicalTrials.gov record NCT02724254. Inclusion in this directory is not an endorsement.